Literature DB >> 21528672

Immunohistochemical assessment of MGMT expression and p53 mutation in glioblastoma multiforme.

Marziyeh Lotfi1, Sima Afsharnezhad, Hamid Reza Raziee, Kamran Ghaffarzadegan, Samaneh Sharif, Jamal Shamsara, Sara Lary, Javad Behravan.   

Abstract

AIMS AND
BACKGROUND: The prognosis of glioblastoma multiforme (GBM) remains poor despite advances in surgery and adjuvant therapies. TP53 and O6-methylguanine-DNA methyltransferase (MGM) are tumor suppressor genes that are implicated in GBM resistance to radiation and chemotherapy. In order to assess the expression of the protein products of these two genes, 50 GBM samples were analyzed in this study.
METHODS: Demographic and clinical data along with postsurgery tumor samples from 50 GBM patients were collected from the pathology archive. MGMT and p53 protein expression was evaluated by immunohistochemistry.
RESULTS: 52% of cases had mutated p53, predominantly expressed in the nuclei of tumor cells. MGMT immunohistochemistry was negative in 35 (70%) patients and positive in 15 (30%) others. Immunohistochemistry-negative specimens for MGMT expression showed a significantly higher expression of mutant p53 (P = 0.03).
CONCLUSION: MGMT expression was significantly lower in cells bearing p53 mutation. This indicates that there is a tendency for p53 activity to decline with MGMT inactivation. However, this study could not deduce which protein was the regulator of the other.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21528672     DOI: 10.1177/030089161109700118

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  8 in total

1.  Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.

Authors:  Tsubasa Miyazaki; Eiichi Ishikawa; Masahide Matsuda; Hiroyoshi Akutsu; Satoru Osuka; Noriaki Sakamoto; Shingo Takano; Tetsuya Yamamoto; Koji Tsuboi; Akira Matsumura
Journal:  J Neurooncol       Date:  2017-04-26       Impact factor: 4.130

2.  An unbalanced translocation involving loss of 10q26.2 and gain of 11q25 in a pedigree with autism spectrum disorder and cerebellar juvenile pilocytic astrocytoma.

Authors:  Hassan M Minhas; Matthew F Pescosolido; Matthew Schwede; Justyna Piasecka; John Gaitanis; Umadevi Tantravahi; Eric M Morrow
Journal:  Am J Med Genet A       Date:  2013-03-12       Impact factor: 2.802

Review 3.  Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.

Authors:  Guan Jiang; Ai-Jun Jiang; Yong Xin; Lian-Tao Li; Qian Cheng; Jun-Nian Zheng
Journal:  Mol Biol Rep       Date:  2014-07-03       Impact factor: 2.316

Review 4.  Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future?

Authors:  M Hingorani; W P Colley; S Dixit; A M Beavis
Journal:  Br J Radiol       Date:  2012-09       Impact factor: 3.039

5.  Correlation and prognostic significance of PD-L1 and P53 expression in resected primary pulmonary lymphoepithelioma-like carcinoma.

Authors:  Xiang-Yang Yu; Xue-Wen Zhang; Fang Wang; Yong-Bin Lin; Wei-Dong Wang; Yong-Qiang Chen; Lan-Jun Zhang; Ling Cai
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

6.  MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Authors:  Marta Mellai; Oriana Monzeglio; Angela Piazzi; Valentina Caldera; Laura Annovazzi; Paola Cassoni; Guido Valente; Susanna Cordera; Cristina Mocellini; Davide Schiffer
Journal:  J Neurooncol       Date:  2012-05       Impact factor: 4.506

7.  Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.

Authors:  Wei Wu; Jessica L Klockow; Michael Zhang; Famyrah Lafortune; Edwin Chang; Linchun Jin; Yang Wu; Heike E Daldrup-Link
Journal:  Pharmacol Res       Date:  2021-07-21       Impact factor: 10.334

8.  Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.

Authors:  Xia Li; Jie Wei; Yixiong Liu; Peifeng Li; Linni Fan; Yingmei Wang; Mingyang Li; Danhui Zhao; Zhou Yu; Jing Ye; Ying Guo; Qingguo Yan; Shuangping Guo; Zhe Wang
Journal:  Sci Rep       Date:  2017-10-12       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.